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Abstract: Inhibition of bromo-and extra-terminal domain (BET) proteins, epigenetic regulators of
genes involved in cell viability, has been efficiently tested in preclinical models of triple negative
breast cancer (TNBC). However, the use of the selective BET-inhibitor JQ1 on humans is limited
by its very short half-life. Herein, we developed, characterized and tested a novel formulation of
nanoparticles containing JQ1 (N-JQ1) against TNBC in vitro and in vivo. N-JQ1, prepared using the
nanoprecipitation method of preformedpoly-lactid-co-glycolic acid in an aqueous solution containing
JQ1 and poloxamer-188 as a stabilizer, presented a high physico-chemical stability. Treatment of
MDA-MB 157 and MDA-MB 231 TNBC cells with N-JQ1 determined a significant decrease in cell
viability, adhesion and migration. Intra-peritoneal administration (5 days/week for two weeks) of
N-JQ1 in nude mice hosting a xenograft TNBC after flank injection of MDA-MB-231 cells determined
a great reduction in the growth and vascularity of the neoplasm. Moreover, the treatment resulted in
a minimal infiltration of nearby tissues. Finally, the encapsulation of JQ1 in nanoparticles improved
the anticancer efficacy of this epigenetic compound against TNBC in vitro and in vivo, opening the
way to test it in the treatment of TNBC.
Keywords: triple negative breast cancer; targeted therapy; nanoparticles; BET inhibitors; JQ1
1. Introduction
Breast cancer is the most common female malignant tumor around the world, accounting for
approximately 30% of all new cancer diagnoses in women [1,2]. The current classification that
governs the therapeutic approach depends mainly on the expression of the estrogen receptor (ER)
and progesterone receptor (PR), as well as on the amplification status of human epidermal growth
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factor receptor 2 (HER2). The lack of these receptors characterizes triple negative breast cancer (TNBC),
which accounts for 12% to 17% of all breast malignant tumors. This subtype is known to affect younger
women and is associated with a high frequency of distant metastasis and poor prognosis [3]. Only
early-stage TNBC is chemotherapy-sensitive [3], thus the search for more effective treatments is still an
open challenge.
A novel and promising approach is based on the use of compounds able to target the
epigenome of breast cancer cells. In particular, among the molecules that inhibit the transcription of
growth-promoting genes by acting on the “readers” of the acetylated histone marks, the bromo-and
extra-terminal domain (BET) inhibitor JQ1 ((S)-tertbutyl2-(4-(4-chlorophenyl)-2,3,9-trimethyl-
6H-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepin-6-yl)acetate) has shown a strong anti-proliferative
action against TNBC cell lines and xenografts [4–7]. JQ1 acts by competing with acetylated histone
residues, thus removing BET proteins from their chromatin targets. It has been tested for its anticancer
effects in both solid and hematological preclinical models of malignancies [4,8,9].
The potential use of JQ1 on humans, however, is limited by its very short half-life, ~1 h [10],
prompting the need for particulate carriers or specific conjugates to deliver this compound to its
targets. For this purpose, the nanoencapsulation of a drug in a biocompatible polymeric colloidal
system is a pharmaceutical approach widely used in the last decades to increase the pharmacological
efficacy of the active compound, modulate its pharmacokinetic profile and decrease its side effects
and the administration times [11]. In order to obtain nanosystems able to deliver various active
compounds against cancer cells, among the various polymeric biomaterials, we and others have used
the poly-lactid-co-glycolic acid (PLGA) polymer, which is approved by the U.S. FDA and EMA for
pharmaceutical application [12–14].
In this work, we have developed and characterized the properties of PLGA nanoparticles
containing JQ1 (N-JQ1) and evaluated the anticancer efficacy of this new formulation against TNBC
cells in vitro and in vivo.
2. Results
2.1. Physico-Chemical Characterization of the Nanosystems
The first step of this investigation was focused on the development and evaluation of the
physico-chemical properties of JQ1-loaded PLGA nanoparticles. The polymeric nanosystems were
characterized by a mean diameter of 130–150 nm, a good size distribution and a negative surface
charge (Table 1). The encapsulation of JQ1 did not compromise the aforesaid parameters up to a drug
concentration of 0.5 mg/mL, confirming the peculiar properties of PLGA as a useful biomaterial in the
development of colloidal systems for the delivery of lipophilic active compounds [15]. The obtained
results are in agreement with those previously described by our research team when other lipophilic
compounds have been entrapped within PLGA nanoparticles [16–18].
Table 1. Physico-chemical properties of poly-lactid-co-glycolic acid (PLGA) nanosystems loaded
with JQ1.
JQ1 (mg/mL) Mean Sizes (nm) Polydispersity Index Zeta Potential (mV)
− 130 ± 1 0.134 ± 0.01 −24 ± 1
0.1 145 ± 3 * 0.142 ± 0.04 −23 ± 2
0.25 148 ± 2 * 0.157 ± 0.05 −23 ± 1
0.5 158 ± 2 * 0.171 ± 0.04 −18 ± 2
1 275 ± 12 ** 0.335 ± 0.15 −16 ± 2
* p < 0.05; ** p < 0.01 vs. empty formulation.
The evaluation of backscattering and transmittance profiles of the various systems demonstrated
a strong stability of nanoparticles (Figure 1A). Moreover, the temperature did not compromise the
aforesaid parameters, demonstrating a great stability of the systems at 37 ◦C (Figure 1B). In fact,
Cancers 2020, 12, 91 3 of 14
the Turbiscan Stability Index (TSI) profiles of the formulations were characterized by the absence of
significant variations over the time, confirming the absence of sediment, flocculation or creaming.
The evaluation of the entrapment efficiency showed a proportional improvement of the retention
rate of the active compound when the concentration of JQ1 added during the preparation steps of
nanosystems was increased (Figure 1C). Moreover, the drug leakage from the polymeric colloidal
structure was prolonged and influenced by the concentration of the active compound; namely, a full
leakage of the entrapped compound was obtained after 48 h (Figure 1D).
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MDA-MB 231 and MDA-MB 157 cells (Figure 2). In particular, a decrease of approximately 50% vs. 
untreated cells was observed at the 0.05 µM concentration of N-JQ1 in MDA-MB 231 cells, with a 
significantly stronger effect compared with JQ1. Similar effects were detected in MDA-MB 157 cells, 
but with an EC50 of 0.5 µM (Figure 2). 
Figure 1. Evaluation of the physical stability of the various nanoformulations. (A) Transmittance (∆T)
and backscattering (∆BS) profiles of (a) empty PLGA nanoparticles and (b) nanosystems prepared with
JQ1 (0.5 mg/mL) using Turbiscan Lab. Results representative of three independent experiments are
shown. (B) Turbiscan Stability Index (TSI) profiles of PLGA nanoparticles as empty formulation or
prepared with JQ1 (0.5 mg/mL) as a function of time and temperature. (C) Entrapment efficiency of JQ1
in PLGA nanoparticles as a function of the drug concentration used. (D) Release profile of JQ1 from
PLGA nanoparticles as a function of the entrapped drug concentration and incubation time. Values
represent the mean of three different experiments ± SD.
2.2. Effects of JQ1-Loaded Nanoparticles on Growth, Migration and Adhesion of TNBC Cells In Vitro
Treatment for 48 h with the biocompatible nanoformulation containing JQ1 (N-JQ1) at various
concentrations (0.005, 0.05, 0.5 and 5 µM) determined a significant reduction in viability of both
MDA-MB 231 and MDA-MB 157 cells (Figure 2). In particular, a decrease of approximately 50% vs.
untreated cells was observed at the 0.05 µM concentration of N-JQ1 in MDA-MB 231 cells, with a
significantly stronger effect compared with JQ1. Similar effects were detected in MDA-MB 157 cells,
but with an EC50 of 0.5 µM (Figure 2).
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Figure 3. Effects of N-JQ1 on adhesion and migration properties of TNBC. MDA-MB 231 and 
MD-MB 157 cells were prepared for adhesion and migration assays as indicated in methods. Each 
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Figure 2. Effects on TNBC cell viability. MDA-MB 231 and MDA-MB 157 cells were treated with JQ1
diluted in PBS + 5% PEG 400 + 5% TWEEN (JQ1) or encapsulated in nanoparticles (N-JQ1). Effects on
viability were analyzed by MTT assay. Each experiment was performed in triplicate and values are
expressed in % over Control, as means± SD. Statistical analysis was performed using the Tukey–Kramer
multiple comparisons test. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. Control; ◦◦ p < 0.01 vs. JQ1. Control,
cells treated with JQ1 vehicle (white bars) or empty nanoparticles (black bars).
Treatment with N-JQ1 0.05 µM also induced a significant reduction in adhesion and migration of
MDA-MB 231 (~40% and ~5 %, respectively) an MDA-MB 157 (~40% and ~70%, respectively) cells
compared to the vehicle treatment (Figur 3). Again, in MDA-MB 231 cells, the effects of N-JQ1 were
stronger th n those of JQ1 (Figure 3).
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3. Effects of N-JQ1 on adhesion and migration pr perties of TNBC. MDA-MB 231 and MD-MB
157 cells were prepared for adh sion and migration assays as indicated in methods. Each experiment
was performed in triplicate and values re expressed in % over Contr l, as means ± SD. Statistical
analys s w s performed using th one-way ANOVA test. * p < 0.05, ** p < 0.01, *** p . 01 vs. Control;
◦◦◦ p < 0.001 vs. JQ1. Repre entative imag s of stained c lls after migration ssays are sh wn. Control,
cells treated with JQ1 vehicle (white bars) or empty nanoparticles (black bars). Scale bar: 50 µm.
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Altogether, these preliminary data in vitro demonstrated that the obtained nanoformulation
preserves and increases the antitumor efficacy of JQ1, and supported our choice to continue the study
using an in vivo experimental model.
2.3. Effects of JQ1-Loaded Nanoparticles on Breast Cancer Xenograft In Vivo
To check the anticancer activity of N-JQ1 against TNBC in vivo, we administered N-JQ1 in athymic
nude mice hosting xenograft tumors obtained by intrascapular injection of MDA-MB 231 cells in 0.1
mL of Matrigel. Another group of animals was treated with JQ1 diluted in PBS + 5% PEG 400 + 5%
TWEEN 80% (JQ1). As controls, we used animals treated with unloaded nanoparticles (N-empty)
or PBS + 5% PEG 400 + 5% TWEEN 80 (Control). These treatments were well tolerated since no
modifications of body weight or of food and water consumption as well as no evidence of reduced
motor function were detected.
As shown in Figure 4A, tumor growth was decreased in the mice treated with JQ1. Interestingly,
a more significant regression of tumor growth was observed in the mice treated with N-JQ1 (Figure 4A).
At the end of treatments, tumors of the mice treated with N-JQ1 presented lower weights and sizes than
the group of controls or the one treated with the empty nanoparticles (N-empty). A significant difference
was also noted between the groups treated with N-JQ1 versus those receiving JQ1 (Figure 4B,C).
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Figure 4. Effects of N-JQ1 treatment on xenograft tumor growth obtained after injection of MDA-MB
231 cells into the intrascapular region of female athymic nude mice. JQ1 (20 mg/kg) diluted in PBS
+ 5% PEG 400 + 5% TWEEN 80 (JQ1), nanoparticles containing JQ1 20 mg/Kg (N-JQ1), unloaded
nanoparticles (N-empty) and PBS + 5% PEG 400 + 5% TWEEN 80 (Control) were administered by
intraperitoneal injection for 15 days (5 days a week) as described in Methods. (A) tumor volume during
the treatment; (B) tumor weight at sacrifice. Values are expressed as the mean of animal groups ± SD.
Statistical analysis was performed by using the one-way ANOVA test. * p < 0.05, ** p < 0.01 vs. Control
or empty nanoparticles; ◦ p < 0.05 vs. JQ1. (C) images of representative individual tumors for each
group of mice.
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In accordance with the reduced proliferation, immunohistochemical analysis of the tumors showed
a significant reduction of the levels of Ki67 in the tumors treated with N-JQ1 (Figure 5).
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In addition, we noted that the tumors of the control groups, as well as those treated with empty 
nanoparticles were particularly aggressive, exhibiting a large infiltration of the surrounding adipose 
and muscle tissues, which was reduced in the animals treated with JQ1 or N-JQ1 (Figure 6). 
However, no signs of metastases in liver, kidney or lungs were observed at the sacrifice of the 
animals. 
Figure 5. (A) A representative image of immunostaining for Ki67 in tumors of each group of animals,
treated as described in Methods (200×magnification). (B) The percentage of positive over total stained
cells for Ki67 in tumors slices are shown in bar graphs.JQ1, JQ1 (20 mg/kg) diluted in PBS + 5% PEG
400 + 5% TWEEN; N-JQ1, nanoparticles containing JQ1 20 mg/Kg; N-empty, unloaded nanoparticles;
Control, untreated mice. Values are expressed as means ± SD. * p < 0.05 vs. Control; ◦ p < 0.05vs. JQ1.
In addition, we noted that the tumors of the control groups, as well as those treated with empty
nanoparticles were particularly aggressive, exhibiting a large infiltration of the surrounding adipose
and muscle tissues, which was reduced in the animals treated with JQ1 or N-JQ1 (Figure 6). However,
no signs of metastases in liver, kidney or lungs were observed at the sacrifice of the animals.
Moreover, a decreased rate of vascularization was also observed in the tumors of N-JQ1 group vs.
the controls, as revealed by CD31 immunostaining of the vascular compartment of tumors (Figure 7).
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Figure 6. Tumor infiltration of tumor-surrounding tissues. Analyses of tumor tissues by hematoxylin
and eosi stai ing of the four groups of a i als after treatment with JQ1 (20 mg/kg) diluted in PBS
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JQ1 20 mg/Kg (N-JQ1). Black and white arrows indicate muscle and fat infiltrations, respectively.
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Since a decrease in c-Myc expression is a major target of BET inhibitor action, we analyzed 
c-Myc mRNA levels in tumor tissues after N-JQ1 treatment. We found that N-JQ1 significantly 
reduced the expression of c-Myc (Figure 8). 
 
Figure 8. c-Myc mRNA levels in tumor tissues. Control, untreated mice JQ1; N-empty, unloaded 
nanoparticles; JQ1 (20 mg/kg) diluted in PBS + 5% PEG 400 + 5% TWEEN; N-JQ1, nanoparticles 
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Figure 7. Immunohistochemical analysis of CD31 expression. (A) Representative images of
immunostai ing for CD31 in tumors of the f roups of animals reate as d scribed in Methods
(200×magnification). (B) The percentage of t tal positive cells for CD31 tumor i ar graphs.
JQ1, JQ1 (20 mg/kg) diluted in PBS + 5% PEG 400 + 5% TWEEN; N-JQ1, nanoparticles containing JQ1
20 mg/Kg; N-empty, unloaded nanoparticles; Control, untreated mice. Values are expressed as means ±
SD. * p < 0.05, *** p < 0.001 vs. control; ◦ p < 0.05 vs. JQ1.
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Histological examination of liver, kidney and lungs showed normal tissue morphology indicating
a lack of toxicity at the dose of JQ1 used.
Since a decrease in c-Myc expression is a major target of BET inhibitor action, we analyzed c-Myc
mRNA levels in tumor tissues after N-JQ1 treatment. We found that N-JQ1 significantly reduced the
expression of c-Myc (Figure 8).
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3. Discussion
A more effective treatment of the patients with breast cancer unresponsive to chemotherapy after
surgical treatment represents a still unresolved clinical challenge. While good results are being obtained
with the endocrine therapy in patients with tumors expressing ER and/or PR, as well as HER2-targeted
therapies used against tumors with HER2 amplification, no efficacious drugs are available for the
TNBC, the most aggressive breast neoplasm marked by early relapse and a predominance of distant
metastases [3,19].
Many approaches are currently under investigation, including the search for molecular targets,
potential candidates for selective treatments [20]. For this purpose, targeting histone activity in
regulating gene expression by acting on epigenome “readers” is a promising approach for the treatment
of various malignancies, including TNBC [9,21,22]. In particular, JQ1 is a first-in-class selective BET
bromodomain inhibitor [23], which acts by competitively binding with high affinity to the acetyl-lysine
hydrophobic pocket of BRD4 [24,25]. Thus, it displaces BET bromodomains from chromatin, interfering
with BRD4 function and leading to growth arrest and promotion of apoptosis in tumor cells [26].
A major problem, which may limit the use of JQ1 in humans, is represented by its very short
half-life [10]. In this work, to overcome the rapid degradation of JQ1, we prepared, characterized and
then tested in vitro and in vivo in preclinical models of TNBC a novel formulation of nanodevices
loaded with JQ1, obtaining a compound with high stability in physiological solutions. We found
that treatment of TNBC cells with N-JQ1 determined a significant decrease of cell viability and a
reduction of cell adhesion and migration. These results prompted us to evaluate the effects of this
novel formulation in vivo. Intra-peritoneal (i.p.) administration of N-JQ1 in nude mice hosting a
xenograft cancer obtained by flank injection of MDA-MB 231 cells, determined a great reduction in the
growth of the neoplasm compared with tumors in mice receiving empty nanoparticles, associated with
a minimal infiltration of nearby tissues and a reduced vascularity of the tumors. The latter effects are
particularly relevant, considering the aggressive behavior of these neoplasms. In addition, no toxic
effects were observed at the doses used.
A well-recognized approach able to prolong the plasmatic half-life of a colloidal system is based
on the coating of its surface by means of hydrophilic derivatives (as in the case of PEG) with the
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aim of decreasing its identification and elimination [27]. However, the multiple administration of
PEG-coated systems determines the appearance of an accelerated blood clearance (the so-called
ABC phenomenon) [28,29]. For this reason, the PLGA nanoparticles proposed in our work were
developed by using the poloxamer 188 as a stabilizer because it can confer long circulating properties
to the particles, avoiding the use of PEG [30,31]. It is important to evidence that DMSO (alone or
in combination with 2-hydroxypropyl-β-cyclodextrin) and a surfactant-based system made up of
Tween 80 and PEG, which have been used to solubilize the drug (“free JQ1”) in the in vitro and in vivo
experiments [32,33], are mixtures associated with several adverse events on humans. Thus, their use
is discouraged by the FDA reports. To the best of our knowledge, no similar drawbacks have been
reported by using the biomaterials of our PLGA-basednanoparticles. The formulation used to deliver
JQ1 in the present study, in addition to its high physical stability, is biocompatible and is made up of
components already approved for human applications [34–36].
Various other formulations have been developed in order to entrap JQ1;
bisphosphonate-functionalized hydroxyapatite-, phospholipid- and chitosan-based nanostructures
containing the active compound have been characterized and proposed for the treatment
of various diseases, including osteosarcoma, glioma and liver fibrosis, respectively [37–39].
Biomimetic nanoclusters made up of the components of the platelet membrane and
polyamidoamine–polyvalerolactone–COOH (PAMAM–PVL–COOH) have also been described as a
potential endothelium-protective anti-restenotic system, improving the peculiar pharmacological
properties of JQ1 [40]. Other potential advantages of our biocompatible systems are (i) to protect
the drug from the chemical, physical and enzymatic degradation;(ii) to localize high amounts of
compound in the cells as “cargo”, modulating its cell availability as a function of the leakage profile
from the carriers; and (iii) to contrast the mechanisms of cell resistance by peculiar properties of
specific components of the formulation (for example the inhibition of PgP eﬄux pumps exerted
by various poloxamerderivatives). Furthermore, the possibility of co-encapsulation of other active
compounds offered by this kind of nanoparticles may represent an additional advancement of the
anticancer features of this nanoformulation. Indeed, the recent direction of the research of anticancer
use of BET inhibitors suggests the use of combinations with other chemotherapeutics, including
associations inside the same delivery biosystems [9,22,38,41,42].
Findings reported herein are very promising to propose the in vivo use of JQ1 in TNBC patients.
Obviously, the biodistribution and pharmacokinetic profiles of the proposed nanoformulation need
further investigation in order to understand the tissue distribution of this nanomedicine and to define
the best administration regimen.
4. Methods
4.1. Preparation and Characterization of JQ1-Loaded PLGA Nanoparticles
PLGA nanoparticles containing JQ1 (0.1–1 mg/mL) were prepared as previously described [16].
Briefly, 2 mL of acetone containing various amounts of drug and PLGA (0.6% w/v) (Sigma Aldrich,
Milan, Italy) were mixed with an aqueous solution (5 mL) enriched with poloxamer 188 (1% w/v)
(Pluronic® PE 6800; BASF, Aktiengesellschaft, Ludwigshafen, Germany) by an Ultraturrax (Ultraturrax
T25, IKA®Werke) at 24,000 rpm for 1 min. Successively, the suspension was purified and characterized
as previously reported [16]. The physico-chemical properties of PLGA nanoparticles were investigated
by photon correlation spectroscopy in order to evaluate the mean diameter, size distribution and surface
charge [43]. The physical stability of nanoparticles was evaluated as a function of the temperature by
using the Turbiscan Lab® analyzer according to procedures described elsewhere [44]. The amount
of JQ1 retained by the PLGA nanoparticles was evaluated by a spectrophotometric method; briefly,
the systems were centrifuged (70,000 rpm, 4 ◦C for 1 h, Optima TL Ultracentrifuge, Beckman Coulter,
Milan, Italy) and the pellet dissolved in acetone. The solvent was then removed under a nitrogen flux
and JQ1 solubilized in ethanol and analyzed by a spectrophotometer at the wavelength of 256 nm.
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The entrapment efficiency (EE%) of JQ1 was evaluated according to the following equation: EE% =
De/Da × 100, where De is the amount of entrapped JQ1 and Da is the amount of active compound used
during the preparation of the colloidal formulations. The release profile of JQ1 from the polymeric
systems was investigated by the dialysis method [45].
4.2. TNBC Cell Lines and Proliferation Assay
MDA-MB 231 and MDA-MB 157, human breast cancer epithelial cells widely used as models of
TNBC for characteristics of growth and progression, were purchased from the American Type Culture
Collection (Manassas, VI, USA), and cultured as previously reported [21]. Cell proliferation was
evaluated by MTT assay [46], performed in 96-well plates containing MDA-MB 231 and MDA-MB 157
cells seeded at a concentration of 5 × 103 and 3.5 × 103/well, respectively, and maintained in medium
with 10% foetal bovine serum (FBS). After treatment with JQ1 diluted in DMSO as vehicle, empty
nanoparticles or nanoparticles containing different concentrations of JQ1 (N-JQ1) for 48 h, the crystals of
formazan were quantified with a microplate spectrophotometer (Thermo Fisher Multiskan FC, Thermo
Fisher Scientific Inc., Waltham, MA, USA) at a wavelength of 540 nm and a reference wavelength of
690 nm. Results are expressed as percentages over untreated cells (JQ1 vehicle or empty nanoparticles)
indicated as Control.
4.3. Adhesion and Migration Assay
Adhesion and migration assays were performed as previously described [47]. The cells were
seeded in 6-well plates (160 × 103 or 130 ×103 per well) and incubated for 48 h with JQ1 or N-JQ1
0.05 µM. For the adhesion assay, 5 × 104 cells were plated into 24-well plates coated with collagen I(BD
Biosciences, Milan, Italy) and after 1 h of incubation, cells were stained with 0.1% Crystal Violet solution,
solubilized in 10% acetic acid. Cell attachment was quantified by measurement of absorbance at 560
nm with a Thermo Fisher Multiskan FC spectrophotometer, Thermo Fisher Scientific Inc., Waltham,
MA, USA).
For the migration assay, 60 × 103 cells, suspended in serum-free medium containing 1% BSA,
were plated in the upper chamber of the transwell inserts with 8 µm pores (Costar, Euroclone, Milan,
Italy). The lower chamber contained 600 µL of medium and 10% FBS as a chemotactic agent. After 6 h
of incubation with JQ1 or N-JQ1, migrated cells were counted using a microscope (magnification 10×)
provided with an eyepiece and equipped with a counting grid. Images of migrated cells were captured
by microscope (Leica BM5500 B), equipped with a 20× objective.
In all experiments, cells treated with JQ1 vehicle or empty nanoparticles were used as controls.
Results are expressed as percentages over the control.
4.4. Xenograft Model Development and Treatments
Five-week-old female athymic nude mice (n = 20) (Envigo, Huntingdon, UK) were maintained
under specific pathogen-free conditions in sterile, ventilated microisolator cages at a constant
temperature (24–26 ◦C), constant humidity (30%–50%) and a 12 h light/dark cycle. Sterilized food
and tap water were given ad libitum. A total of 5 × 106 MDA-MB 231 cells in 0.1 mL of Matrigel (BD
Biosciences) were injected into intrascapular region of the mice. Treatment was initiated when the
tumors reached an average volume of ~150 mm3. The mice were then randomly divided into the
following four groups: animals treated with PBS + 5% PEG 400 + 5% TWEEN 80 (control), animals
treated with JQ1 20 mg/Kg diluted in PBS + 5% PEG 400 + 5% TWEEN 80 (JQ1), animals treated with
an aqueous suspension made up of unloaded nanoparticles (N-empty) or nanoparticles containing JQ1
20 mg/Kg (N-JQ1). The treatment was carried out for 5 days a week for two weeks by i.p. injection.
Tumor development was followed at 2-day intervals by caliper measurements along two orthogonal
axes: length (L) and width (W). The volume (V) of tumors was estimated by the following formula: V
= L (W2)/2 [48]. Body weight, feeding behavior and motor activity of the mice were used as indicators
of general health. At the end of each experiment, animals were euthanized by cervical dislocation after
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anesthesia with Avertin (2, 2, 2-Tribromoethanol, 250 mg/kg, i.p.), and the xenografts were harvested
and subjected to downstream end-point analysis. Tumor tissues were excised, weighed and stored in
formalin 10% for immunohistochemistry. All animals were maintained and handled in accordance with
the recommendation of the Guidelines for the Care and Use of Laboratory Animals and experiments
were approved by the Animal Care Committee of University of Calabria (OPBA), Italy (ethic code:
533/2019-PR, approved on 19 July 2019).
4.5. Histopathological Study and Immunohistochemistry
Tumor tissues were fixed in 10% formalinand subsequently processed with an automated tissue
processor (Leica ASP 6025) and paraffin embedded. Sections (4 µm-thick) were mounted on coated
glass slides, and heated at 60 ◦C for 60 min. One section was stained with hematoxylin and eosin
for light microscopy analysis, while other sections were prepared for immunohistochemical analyses
for which standard protocol was applied [49]. Tissue sections for immunohistochemical staining was
performed with an automated immunostainer (Bond RX Max, Leica Biosystems, Buccinasco, Milan,
Italy) using anti-CD 31 (ready to use, clone JC70A, Dako Agilent, Santa Clara, CA, USA) and anti-Ki67
(1:500) (ab6526, Abcam, Cambridge, UK) antibodies. A direct count of positive cells was conducted on
ten fields for all the cases. The sections were stained with DAB and then slightly counterstained with
Mayer hematoxylin, to be analyzed using a microscope (Leica LDM108) and digital image-capture
computer system. Two senior pathologists (ChM and SC) analyzed the immunohistochemical results
independently, blind to treatment, discriminating positively (brown color) and negatively (blue color)
stained cells through manual counting. The results are expressed as percentage of positive cells.
4.6. RNA Extraction and Real Time PCR
The Trizol method (Thermo Fisher Scientific, Inc.) was used to extract total RNA from tumoral
tissues. c-Myc gene levels were determined with real-time-PCR, using Platinum Sybr Green QPCR
supermix and the ABI Prism 7300 Sequence Detection Systems (Applied Biosystems, Foster City,
CA, USA), as previously described [12]. The β-actin gene was used as an endogenous reference.
All amplification reactions were performed in triplicate, and the threshold cycles (identified with
Applied Biosystems, SDS software) of the three reactions were averaged. Results were obtained by the
2−∆∆Ct method. Oligonucleotide primers were purchased from Sigma-Aldrich, and their sequences are
available upon request.
4.7. Statistical Analysis
Results were analyzed by one-way ANOVA followed by the Tukey–Kramer multiple comparisons
test or Student’s t-test. All results are expressed as mean ± standard deviation (SD) and p values
lower than 0.05 were considered statistically significant. All statistical analyses were performed using
GraphPad Prism version 5.0 statistical software (GraphPad Software Inc., San Diego, CA, USA).
5. Conclusions
The present findings demonstrate that the encapsulation of JQ1 in nanoparticles, by protecting
this compound and assuring a more efficient targeting to tumor cells, improves the anticancer efficacy
of this innovative formulation against preclinical models of TNBC in vitro and in vivo, opening the
way for a potential use in the treatment of TNBC.
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